Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

ABSTRACT:

Background

Patients with acute myeloid leukemia (AML) without complete remission (CR) or in first relapse (Rel1) can have extended leukemia control and survival after allogeneic hematopoietic cell transplantation (HCT). For patients in Rel1 or primary induction failure (PIF), transplantation versus treatment to achieve a second CR (CR2) and subsequent HCT might yield similar outcomes, but available comparative data are scarce.

Methods

Survival was analyzed in 4682 HCT recipients according to disease status: PIF (N = 1440), Rel1 (failing ≥1 reinduction; N = 1256), and CR2 (N = 1986).

Results

Patient, disease, and transplantation characteristics were similar, except that patients in CR2 more often had performance scores of 90% to 100%, de novo AML, and longer CR1 durati

SUBMITTER: Weisdorf DJ 

PROVIDER: S-EPMC5445001 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature